Immunotherapy for solid tumours progresses to human trials
Drug Discovery World
AUGUST 14, 2023
Research partners in the UK are progressing their orally available small molecule cancer immunotherapy drug into clinical development as a treatment for advanced solid tumours. Sosei Group and Cancer Research UK announced that the first patient has been dosed in a Phase I/IIa clinical trial evaluating Sosei Heptares’ immunotherapy drug HTL0039732. HTL0039732 works by blocking signalling through a specific type of prostaglandin receptor, the prostaglandin E2 (PGE2)-type prostanoid receptor 4 (EP4
Let's personalize your content